1. Ferlay, J., et al., Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 2013. 49(6): p. 1374-403. [DOI via Crossref] [Pubmed] | | 2. Znaor, A., et al., Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe. Eur J Cancer, 2013. 49(7): p. 1683-91. [DOI via Crossref] [Pubmed] | | 3. Jemal, A., et al., Cancer statistics, 2010. CA Cancer J Clin, 2010. 60(5): p. 277-300. [DOI via Crossref] [Pubmed] | | 4. DeSantis, C., et al., Breast cancer statistics, 2013. CA Cancer J Clin, 2014. 64(1): p. 52-62. [DOI via Crossref] [Pubmed] | | 5. Smith, H.O., et al., Hormone replacement therapy in the menopause: a pro opinion. CA Cancer J Clin, 1996. 46(6): p. 343-63. [DOI via Crossref] [Pubmed] | | 6. Warnberg, F., et al., Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev, 2001. 10(5): p. 495-9. [Pubmed] | | 7. Cossetti, R.J., et al., Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol, 2015. 33(1): p. 65-73. [DOI via Crossref] [Pubmed] | | 8. Luengo-Fernandez, R., et al., Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol, 2013. 14(12): p. 1165-74. [DOI via Crossref] | | 9. Sikora, K., Molecular biology and the treatment of cancer. Clin Radiol, 1985. 36(2): p. 117-24. [DOI via Crossref] | | 10. Busch, H., A general concept for molecular biology of cancer. Cancer Res, 1976. 36(11 Pt. 2): p. 4291-4. [Pubmed] | | 11. Korhonen, T., et al., The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast, 2013. 22(6): p. 1119-24. [DOI via Crossref] [Pubmed] | | 12. Dhillon, A.S., et al., MAP kinase signalling pathways in cancer. Oncogene, 2007. 26(22): p. 3279-90. [DOI via Crossref] [Pubmed] | | 13. Krishna, M. and H. Narang, The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci, 2008. 65(22): p. 3525-44. [DOI via Crossref] [Pubmed] | | 14. Whyte, J., et al., Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res, 2009. 11(5): p. 209. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 15. Haagenson, K.K. and G.S. Wu, The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev, 2010. 29(1): p. 143-9. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 16. Mitri, Z., T. Constantine, and R. O'Regan, The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract, 2012. 2012: p. 743193. [Pubmed] [PMC Free Fulltext] | | 17. Munster, P.N., et al., Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res, 2002. 62(11): p. 3132-7. [Pubmed] | | 18. Reddy, K.B., S.M. Nabha, and N. Atanaskova, Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 2003. 22(4): p. 395-403. [DOI via Crossref] [Pubmed] | | 19. Krueger, J.S., et al., Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene, 2001. 20(31): p. 4209-18. [DOI via Crossref] [Pubmed] | | 20. Wu, J.Y., et al., Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. Int J Cancer, 2006. 118(5): p. 1215-26. [DOI via Crossref] [Pubmed] | | 21. Dyrstad, S.W., et al., Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat, 2015. 149(3): p. 569-75. [DOI via Crossref] [Pubmed] | | 22. Moon, H.J., et al., Breast papilloma without atypia and risk of breast carcinoma. Breast J, 2014. 20(5): p. 525-33. [DOI via Crossref] [Pubmed] | | 23. Dupont, W.D., et al., Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med, 1994. 331(1): p. 10-5. [DOI via Crossref] [Pubmed] | | 24. Gobbi, H., et al., Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst, 1999. 91(24): p. 2096-101. [DOI via Crossref] [Pubmed] | | 25. Novitskiy, S.V., et al., TGF-beta receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov, 2011. 1(5): p. 430-41. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 26. Jacobs, T.W., et al., Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med, 1999. 340(6): p. 430-6. [DOI via Crossref] [Pubmed] | | 27. Collins, L.C., et al., Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer, 2007. 109(2): p. 180-7. [DOI via Crossref] [Pubmed] | | 28. Meshkat, B., et al., A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer. Breast, 2015. 24(3): p. 278-82. [DOI via Crossref] [Pubmed] | | 29. Duijm, L.E., et al., Value of breast imaging in women with painful breasts: observational follow up study. BMJ, 1998. 317(7171): p. 1492-5. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 30. Klein, C.A., Cancer. The metastasis cascade. Science, 2008. 321(5897): p. 1785-7. [DOI via Crossref] [Pubmed] | | 31. Wirtz, D., K. Konstantopoulos, and P.C. Searson, The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer, 2011. 11(7): p. 512-22. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 32. Lacroix, M., Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer, 2006. 13(4): p. 1033-67. [DOI via Crossref] [Pubmed] | | 33. Kozlowski, J., A. Kozlowska, and J. Kocki, Breast cancer metastasis - insight into selected molecular mechanisms of the phenomenon. Postepy Hig Med Dosw (Online), 2015. 69: p. 447-51. [DOI via Crossref] | | 34. Vega, F.M. and A.J. Ridley, Rho GTPases in cancer cell biology. FEBS Lett, 2008. 582(14): p. 2093-101. [DOI via Crossref] [Pubmed] | | 35. Parri, M. and P. Chiarugi, Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal, 2010. 8: p. 23. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 36. Xu, Y., et al., The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin beta(1). Sci Signal, 2014. 7(330): p. ra58. [DOI via Crossref] [Pubmed] | | 37. Inuzuka, M., et al., [Integrins involved in tumor invasion and metastasis]. Nihon Rinsho, 1995. 53(7): p. 1631-6. [Pubmed] | | 38. Etienne-Manneville, S. and A. Hall, Rho GTPases in cell biology. Nature, 2002. 420(6916): p. 629-35. [DOI via Crossref] [Pubmed] | | 39. Bonadonna, G., et al., Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol, 1998. 16(1): p. 93-100. [Pubmed] | | 40. van der Hage, J.A., et al., Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol, 2001. 19(22): p. 4224-37. [Pubmed] | |
|
|